Nexalin Technology, Inc. (NXL) NASDAQ
0.34
-0.0004(-0.12%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.34
-0.0004(-0.12%)
Currency In USD
Address
1776 Yorktown
Houston, TX 77056
United States of America (the)
Phone
713 660 1100
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
6
First IPO Date
September 16, 2022
| Name | Title | Pay | Year Born |
| Mark White | President, Chief Executive Officer & Director | 598,000 | 1962 |
| David Owens | Chief Medical Officer, Member of Scientific Advisory Board & Director | 50,600 | 1962 |
| Carolyn Shelton | Executive Vice President of Clinical, Quality & Regulatory Affairs | 340,000 | 1963 |
| John Patrick Claude | Co-Founder and Director of Engineering & Development | 0 | N/A |
| Justin Van Fleet | Chief Financial Officer | 0 | 1981 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.